Ann Boriack-Sjodin
Company: Takeda Pharmaceutical
Job title: Executive Director & Global Head of Structural Biology
Seminars:
Panel & Roundtable Discussion: Translating Cross-Modality Learnings & Charting the Future of Structure-Based Drug Design 4:15 pm
As we wrap up a day of case studies and innovation, join us for a dynamic session that combines expert perspectives with interactive discussion to reflect on cross-modality structural biology strategies and explore the future of structure-based drug design.
- What are the emerging trends in structure-based drug design that hold the most promise for advancing therapeutics across different modalities?
- How can the integration of various structural biology techniques unlock new opportunities for multi-modal therapeutic approaches?
- What areas of structural biology require greater focus or investment to accelerate progress and benefit multiple therapeutic modalities?
- Looking ahead: What are the key scientific or technological breakthroughs we can expect in the next 5-10 years that will transform structure-based drug design?
day: Day 2
